Soru

Zorluk: ZorNeoplastic Processes

A primary care physician evaluates a female patient who reports 14 months of progressively worsening deep pain in her ribs and lower extremities. The patient, a 42-year-old architect, also describes profound proximal muscle weakness, noting that she now requires the use of her arms to stand up from a seated position. She has no significant past medical history and takes no medications. Vital signs are within normal limits. Physical examination reveals tenderness to palpation over the anterior ribs bilaterally and 4/5 strength in the proximal hip flexors.

Laboratory studies reveal the following:

TestResultReference Range
Serum calcium9.1 mg/dL8.4-10.2 mg/dL
Serum phosphorus1.3 mg/dL2.7-4.5 mg/dL
Alkaline phosphatase285 U/L40-120 U/L
Parathyroid hormone, intact35 pg/mL10-65 pg/mL
25-hydroxyvitamin D42 ng/mL20-50 ng/mL
1,25-dihydroxyvitamin D9 pg/mL18-72 pg/mL
Serum creatinine0.8 mg/dL0.6-1.1 mg/dL

Further evaluation shows a fractional excretion of phosphorus of 28% (normal in the setting of hypophosphatemia: <5%). Radiographs of the pelvis demonstrate symmetric, thin, radiolucent lines perpendicular to the cortex of the femoral necks.

Which of the following best describes the underlying paraneoplastic mechanism responsible for this patient's condition, and the most appropriate next step in management to confirm the etiology?

  1. Secretion of a peptide that downregulates proximal tubule sodium-phosphate cotransporters; order a Gallium-68 DOTATATE positron emission tomography scanCevap
  2. B
    Secretion of a protein with structural homology to parathyroid hormone; order a technetium-99m sestamibi scintigraphy scan
  3. C
    Release of local cytokines that stimulate massive osteoclast-mediated bone resorption; order a serum free light chain assay and bone marrow biopsy
  4. D
    Somatic mutations leading to disorganized, hyperactive osteoblast and osteoclast activity; order a technetium-99m skeletal bone scan
  5. E
    Tumor-mediated upregulation of osteoclast activity from an occult primary carcinoma; administer intravenous zoledronic acid

Cevap

The correct mechanism is the ectopic secretion of a peptide (FGF23) that downregulates proximal tubule sodium-phosphate cotransporters, and the most appropriate next step is to order a Gallium-68 DOTATATE positron emission tomography scan.
The correct answer accurately describes the pathophysiology and clinical management of Tumor-Induced Osteomalacia (TIO). The patient's presentation of proximal muscle weakness, bone pain, and pseudofractures (Looser zones) combined with severe hypophosphatemia, high fractional excretion of phosphorus, and normal calcium is pathognomonic. This syndrome is caused by small, typically benign phosphaturic mesenchymal tumors that autonomously secrete fibroblast growth factor 23 (FGF23). FGF23 is a phosphatonin that acts on the renal proximal tubule to downregulate sodium-phosphate cotransporters (NaPi-IIa and NaPi-IIc), causing massive phosphaturia. Concurrently, FGF23 inhibits 1-alpha-hydroxylase, resulting in an inappropriately low level of 1,25-dihydroxyvitamin D (despite normal precursor stores), distinguishing this from primary hyperparathyroidism where 1,25-dihydroxyvitamin D is elevated. Because these mesenchymal tumors are frequently tiny, ubiquitous, and express somatostatin receptors (SSTRs), functional imaging with a Gallium-68 DOTATATE PET/CT scan is the preferred next step to localize the tumor for curative surgical resection.

Adım Adım Çözüm

1
Analyze the metabolic panel and vitamin D indices.
The patient has severe hypophosphatemia with inappropriate renal phosphate wasting (FEPO4 28%), elevated alkaline phosphatase, and low active vitamin D (1,25-OH), despite normal 25-OH vitamin D, calcium, and intact PTH.
To narrow the differential diagnosis of diffuse bone pain and objectively identify the specific mineral metabolism defect.
2
Correlate the laboratory findings with the radiographic presentation.
The presence of symmetric radiolucent lines perpendicular to the cortex (Looser zones or pseudofractures) confirms osteomalacia secondary to chronic hypophosphatemia.
To distinguish defective bone mineralization from other structural causes of bone pain, such as lytic metastases or Paget disease.
3
Identify the exact pathophysiologic mediator responsible for the lab pattern.
The combination of renal phosphate wasting and suppressed 1-alpha-hydroxylase activity in the setting of normal PTH uniquely points to excess fibroblast growth factor 23 (FGF23).
FGF23 is a phosphatonin that acts specifically on the proximal tubule to inhibit both sodium-phosphate cotransporters and 1-alpha-hydroxylase.
4
Determine the diagnostic test of choice to identify the paraneoplastic source.
Select Gallium-68 DOTATATE PET imaging to locate an occult phosphaturic mesenchymal tumor.
These tumors cause Tumor-Induced Osteomalacia (TIO) and characteristically express high levels of somatostatin receptors, making functional SSTR-imaging the gold standard for localization.

Anahtar Kavram

Tumor-induced osteomalacia (TIO) mediated by ectopic FGF23 secretion from phosphaturic mesenchymal tumors.
Tahmini Süre:2m 0s
Bu soruyu puanla